Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration

Collaboration enables Fusion to produce high purity actinium-225 at Company’s GMP manufacturing facility Agreement furthers BWXT Medical’s position as a global leader in medical isotope supply HAMILTON, ON and BOSTON, Nov. 16, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq:…